iCare USA’s EIDON Ultra-Widefield Lens module receives US FDA 510(k) approval

Article

The EIDON Ultra-Widefield Lens module from iCare USA has received 510(k) approval from the FDA for distribution in the US.

iCare USA’s EIDON Ultra-Widefield Lens module receives US FDA 510(k) approval

The EIDON Ultra-Widefield Lens module from iCare USA has received 510(k) approval from the FDA for distribution in the US.

The Ultra-Widefield lens enables infrared, autofluorescence and fluorescein angiography images with up to 200° panoramic view. The lens captures 120 degree images of the retina in a single shot or up to 200 degrees with the “Mosiac” feature. This shows small details, highlighting signs of pathology from the center to the periphery and enables EIDON diagnostics to surpass limitations of conventional diagnostic tools.

The EIDON from iCare is the first TrueColor Confocal system to combine standard fundus imaging with features of Scanning Laser Ophthalmoscopy (SLO) systems. The retinal imaging system provides widefield views in multiple imaging modalities.

The Ultra-Widefield lens can be retrofitted to most of the EIDON fundus imaging systems.

iCare offers clinicians ophthalmic diagnostic tools to detect glaucoma, diabetic retinopathy and age-related macular degeneration (AMD). Their portfolio includes automated TrueColor imaging devices, perimeters and handheld rebound tonometers.

More information about the EIDON Ultra-Widefield lens can be found on the iCare website.

Related Content: Gene Therapy | Retina | Cataract & Refractive

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.